ARL13B-Targeted Drug Discovery Services

Introduction

ADP-ribosylation factor-like protein 13B (ARL13B) is also known as ADP-ribosylation factor-like protein 2-like 1. It is encoded by the ARL13B gene in humans. This gene encodes a member of the ADP-ribosylation factor-like family. The encoded protein is a small GTPase that contains both N-terminal and C-terminal guanine nucleotide-binding motifs. This protein is localized in the cilia and plays a role in cilia formation and in maintenance of cilia. Mutations in this gene are the cause of Joubert syndrome 8. Alternate splicing results in multiple transcript variants. [provided by RefSeq, Mar 2010] At first, ARL13B was identified as a regulator of ciliogenesis and Sonic hedgehog (Shh) signaling. However, recent studies indicated that ARL13B participates in the development of gastric cancer, including promoting carcinogenesis, cell migration, invasion and medulloblastoma formation, which suggested that ARL13B is a potential target to treat gastric cancer.

Direction of Drugs Discovery

• Developing New Clinical Effects on ARL13B from Existing Drugs

Drugs

To be updated

What We Offer

Target Testing

CD BioSciences provides ARL13B testing services by IHC or WB assay. The results of ARL13B testing are used to evaluate the activities of candidates against ARL13B or targeted diseases. You can choose one or more testing ways to detect the level of ARL13B according to your experiment.

Hit Identification (show more)

The goal of early drug discovery is to find novel lead compounds that have the desired potency, selectivity, and ADMET properties for pre-clinical evaluation.
CD BioSciences offers hit identification services to make your finding of targeted compounds more successful and faster.
• High-Throughput Screening
• ARL13B-Targeted in Silico Virtual Screening
• Fragment-Based Screening
• High-Content Screening

Antibody Drugs Development Services (show more)

Antibody drugs exhibit many incomparable advantages, such as high specificity, affinity, and efficiency, which is an emerging direction on targeted drug development. CD BioSciences provides comprehensive services on ARL13B-targeted antibody drugs development with professional technology, extensive experience, and advanced equipment.
• Antibody Preparation Services
• Phage Display Services
• Antibody-Drug Conjugates
• Bispecific Antibody Services
• Antibody Humanization Services

Pharmacological Experiments (show more)

We will create a specific experimental plan according to your requirements, including but not limited to
• Pharmacokinetics / Pharmacodynamics
• Pharmacodynamics
• Pharmacokinetics
• Safety Pharmacology

Disease Models Screening (show more)

We will create specific disease models to accelerate your targeted drug discovery project, including but not limited to
• Diseases—Joubert syndrome.
CD BioSciences will establish the specific disease models according to your requirements to evaluate the inhibitory activity of your candidates targeted ARL13B. We have various cell lines and the species of our animal models cover rats, mice, rabbits, dogs, and non-human primates.

Inquire Us

References

1. Stelzer G.; et al. The GeneCards Suite: From Gene Data Mining to Disease Genome Sequence Analysis , Current Protocols in Bioinformatics(2016), 54:1.30.1 - 1.30.33.doi: 10.1002 / cpbi.5.
2. Wishart DS; et al. DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue): D901-6.
3. Y. Zhou; et al. Therapeutic target database update 2022: facilitating drug discovery with enriched comparative data of targeted agents. Nucleic Acids Research. 50(D1): 1398-1407 (2022). PMID: 34718904.
4. Casalou, C., et al., Arl13b regulates breast cancer cell migration and invasion by controlling integrin-mediated signaling. Cancers (Basel) , 2019. 11(10).